证券日报网讯2月6日，九洲药业（603456）在互动平台回答投资者提问时表示，公司多肽业务具备从多 肽定制化合物到申报注册，最终覆盖商业化GMP生产的一站式服务能力，目前业务发展趋势向好，订 单量和项目数量日益丰富。新增的年产800公斤多肽产能已于2025年正式投产，并已承接具体项目订 单。结合当前业务规划与市场需求，预计2026年公司多肽整体产能利用率将维持在40%-50%左右。 ...

证券代码：603456 证券简称：九洲药业 公告编号：2026-005 浙江九洲药业股份有限公司 关于开立募集资金现金管理产品专用结算账户及 使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理受托方：中国农业银行股份有限公司台州椒江支行营业室（以 下简称"农业银行台州椒江支行"）； 履行的审议程序：浙江九洲药业股份有限公司（以下简称"公司"、 "九洲药业"）于2025年12月9日召开的第八届董事会第十九次会议、第八届审 计委员会第十三次会议，审议通过了《关于使用闲置募集资金进行现金管理的议 案》，同意公司及子公司在保障资金安全及确保不影响募集资金投资项目建设和 使用计划的前提下，使用不超过人民币10亿元的闲置募集资金适时购买安全性高、 流动性好的投资产品（包括但不限于结构性存款、定期存款、大额存单、通知存 款、收益凭证及银行或券商理财产品等），不得为非保本型。期限为自董事会审 议通过之日起不超过12个月，单笔投资产品的期限不超过12个月。本事项无需提 交股东会审议。 ...

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

证券日报网讯1月29日，九洲药业（603456）在互动平台回答投资者提问时表示，股价表现受市场行 情、板块轮动等多重因素影响，公司将持续专注主业发展，不断提升核心竞争力，积极通过规范经营与 透明沟通向市场传递长期投资价值。 ...

Core Viewpoint - The company, Zhejiang Jiuzhou Pharmaceutical Co., Ltd., has announced the use of idle raised funds for cash management, specifically to redeem maturing cash management products and continue cash management activities [1][2]. Cash Management Overview - The entrusted party for cash management is Agricultural Bank of China, Changshu Economic Development Zone Branch [2]. - The board of directors approved the use of up to RMB 1 billion of idle raised funds for cash management, ensuring that it does not affect the construction and use of investment projects [2][7]. - The cash management products include high-security and liquid investment options such as structured deposits, time deposits, large certificates of deposit, notice deposits, income certificates, and bank or brokerage wealth management products [2][7]. Cash Management Details - The amount used for cash management is RMB 30 million [4][5]. - The cash management product involved is a large certificate of deposit with a duration of 6 months [5]. - The company has previously raised RMB 2.5 billion through a non-public offering of shares, with a net amount of RMB 2.49 billion after deducting issuance costs [6]. Purpose of Cash Management - The purpose of cash management is to enhance the efficiency of fund utilization while ensuring the safety of funds and the normal operation of investment projects [3][10]. Risk Management - The company emphasizes that the cash management will only involve high-security and liquid products, minimizing investment risks [8][9]. - Strict adherence to prudent investment principles and confidentiality regarding cash management activities is mandated [9]. Impact on Company - The cash management activities are not expected to affect the implementation of investment projects or the company's future operations, financial status, or cash flow significantly [10].

（文章来源：证券日报） 证券日报网讯 1月28日，九洲药业在互动平台回答投资者提问时表示，公司始终重视投资者回报，如有 相关股份回购计划，将及时进行披露。 ...

证券日报网讯 1月28日，九洲药业在互动平台回答投资者提问时表示，公司将遵循规则要求履行信息披 露义务。 （文章来源：证券日报） ...

证券代码：603456 证券简称：九洲药业 公告编号：2026-004 浙江九洲药业股份有限公司 关于使用闲置募集资金进行现金管理到期赎回并 继续进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理受托方：中国农业银行股份有限公司常熟经济开发区支行（以 下简称"农业银行常熟经济开发区支行"）； 履行的审议程序：浙江九洲药业股份有限公司（以下简称"公司"、"九洲 药业"）于 2025 年 12 月 9 日召开的第八届董事会第十九次会议、第八届审计委 员会第十三次会议，审议通过了《关于使用闲置募集资金进行现金管理的议案》， 同意公司及子公司在保障资金安全及确保不影响募集资金投资项目建设和使用 计划的前提下，使用不超过人民币 10 亿元的闲置募集资金适时购买安全性高、 流动性好的投资产品（包括但不限于结构性存款、定期存款、大额存单、通知存 款、收益凭证及银行或券商理财产品等），不得为非保本型。期限为自董事会审 议通过之日起不超过 12 个月，单笔投资产品的期限不超过 12 个月。本事项无需 提 ...

企业认缴出资总额的 12.987%。根据《上海证券交易所股票上市规则》及《公司 章程》的有关规定，本次对外投资事项无需提交公司董事会、股东会审议批准， 亦不构成关联交易和重大资产重组。 具体内容详见公司于 2025 年 12 月 23 日披露于上海证券交易所官网 （www.sse.com.cn）的《浙江九洲药业股份有限公司关于全资子公司参与投资嘉 兴隆峰创业投资合伙企业（有限合伙）的公告》（公告编号：2025-075）。 证券代码：603456 证券简称：九洲药业 公告编号：2026-003 浙江九洲药业股份有限公司关于全资子公司参与 投资嘉兴隆峰创业投资合伙企业（有限合伙）的进展 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 投资标的名称 | | | 嘉兴隆峰创业投资合伙企业（有限合伙） | | | --- | --- | --- | --- | --- | | 投资金额（万元） | 1,000 | | | | | 投资进展阶段 | 完成 | 终止 | 交易要素变更 | √进展 | | 特别 ...

证券日报网讯1月23日，九洲药业（603456）在互动平台回答投资者提问时表示，股价表现受市场行 情、板块轮动等多重因素影响，公司将持续聚焦主营业务发展，提升可持续盈利能力，优化治理结构， 积极向资本市场传递核心价值，切实为投资者创造长期、稳定的投资回报。 ...